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Behavior changeWe conducted a translational genomic pilot study to evaluate the impact of genomic information related to
colorectal cancer (CRC) risk on psychosocial, behavioral and communication outcomes. In 47 primary care
participants, 96% opted for testing of three single nucleotide polymorphisms (SNPs) related to CRC risk. Participants
averaged 2.5 of 6 possible SNP risk alleles (10% lifetime risk). At 3-months, participants did not report signiﬁcant
increases in cancer worry/distress; over half reported physical activity and dietary changes. SNP risk scores were
unrelated to behavior change at 3-months. Many participants (64%) shared their SNP results, including 28% who
shared results with a physician. In this pilot, genomic risk education, including discussion of other risk factors,
appeared to impact patients' health behaviors, regardless of the level of SNP risk. Future work can compare risk
education with and without SNP results to evaluate if SNP information adds value to existing approaches.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Effective clinical translation of genomic information from low-
penetrance genes into meaningful health improvements remains
elusive. Research to date indicates that genomic information from
single nucleotide polymorphisms (SNPs) may have a limited impact
on long-term behavior change. For example, within the context of
smoking cessation, genomic feedback inﬂuenced smoking quit attempts
[1,2] but these quit attempts do not appear to translate into sustained
smoking cessation [3–5]. Likewise, the evidence for other types of health
behavior change following provision of genomic risk information is
equivocal [6–8]. Large scale studies such as those conducted by the
Coriell Personalized Medicine Collaborative (CPMC) [9] and the NIH
Multiplex Initiative [10] suggest that although participants understood
the genomic information and did not report negative emotional re-
sponses [6,11], behavior change wasminimal. Similarly, among partici-
pants who obtained genomic testing through a Direct-to-Consumerthrough NCI K07CA131172-S2
I P30CA051008, which partially
ce at Lombardi Comprehensive
he responsibility of the authors
he National Cancer Institute or
).
rights reserved.(DTC) commercial company, intentions to improve physical activity,
diet and cancer screening were high, but few actual behavior changes
were noted [12]. In contrast, in a different DTC study sample, partici-
pants reported change in physical activity, diet and communication of
genomic results to healthcare providers [7], particularly among people
who had personal or family history of disease. Likewise, research
conducted with individuals selected for family history reported changes
in vitamin intake after disclosure of APOEe4 status, a SNP related to
Alzheimer's disease [13].
Behavioral researchhashastened the translationof genetic discoveries
into clinical practice [14]. Currently, the “vision” for genomics includes
use of genomic information to facilitate health behavior change efforts
[15]. The continuum of translational genomic research described by
Khoury and colleagues [16] includes the translation of genomic discover-
ies to improve public health. However, to date, more than 95% of funded
cancer genomic research has focused on the early stages of genomic dis-
covery. The potential for genomic advances to impact population health
will not be realized unless and until we engage in translational research
on implementation and outcomes of genomic testing [16].
Few studies to date have examined multiple health behavior change
outcomes within the context of pre- and post-test cancer genomic edu-
cation and testing [9,10,13]. We conducted a pilot study with primary
care patients to evaluate people's responses to SNP testing for colorectal
cancer (CRC) risk.We elected to examine risk for CRC given that it occurs
in both men and women, has effective screening/prevention guidelines,
124 K.D. Graves et al. / Genomics 102 (2013) 123–130hasmodiﬁable lifestyle risk factors (e.g., physical activity, diet), and has a
growing evidence base of identiﬁed SNPs related to CRC risk [17].
2. Materials and methods
2.1. Participants
We invited male and female patients from Georgetown University
Hospital's Division of General Internal Medicine to participate in a
study offering free genomic testing for a research panel of three
SNPs related to CRC risk. We recruited participants in-person in the
clinic waiting room and through mailed study invitation letters. Eligi-
bility criteria included age ≥ 40 years, ability to read and understand
English and ability to provide informed consent. We did not exclude
anyone based on prior personal or family cancer history. All study
procedures were approved by the Institutional Review Board at
Georgetown University/MedStar Health. The recruitment materials
clearly explained that SNP testing was optional. The consent docu-
ment emphasized the uncertain clinical utility of SNP testing and de-
scribed the risks and beneﬁts of study participation and SNP testing
[18].
2.2. Procedures
2.2.1. Overview
After providing written informed consent, participants attended
pre- and post-test education sessionswith a certiﬁed genetic counselor.
Sessions were held in person or by telephone and were audio-recorded
if participants agreed. We conducted four brief assessments. Partici-
pants completed two assessments at the time of the ﬁrst education ses-
sion, one as a baseline (pre-education and pre-testing) and the other
conducted immediately post-education, but before testing. Immediate-
ly after the second education session inwhich participants learned their
SNP risk scores, they completed a post-test assessment. Finally, partici-
pants completed follow-up assessments 3-months after receipt of their
SNP results. Participants received gift cards valued at $30 for completion
of the initial education session and baseline survey, $25 for completion
of the result education session and immediate post-test survey and $10
for completion of the 3-month follow-up survey.
2.2.2. Genomic education sessions
Our transdisciplinary research team developed the content of the
printed materials utilized by the genetic counselor during the educa-
tion sessions. Details of the material content have been published
elsewhere [18]. Brieﬂy, the pre-test materials included descriptions
of risk factors for CRC; deﬁnitions of SNPs and how SNPs might be re-
lated to CRC risk; the beneﬁts, limitations and risks of SNP testing and
steps to reduce risk of CRC. We emphasized the uncertain clinical util-
ity of SNP testing for CRC as well as the uncertainties surroundingTable 1
Selected panel of three CRC SNPs.
SNP/closest gene Alleles Approximate risk odds ratio;
95% conﬁdence interval
SNP f
GUH
8q24.21 rs6983267 [19]
POU5F1P1, MYC [48]
GG OR = 1.68; 1.21–2.33 0.79
GT OR = 1.39; 1.03–1.88 0.21
TT OR = 1.0 0
15q13.3 rs4779584 [20] CRAC1 TT OR = 1.70; 1.41–2.04 0.36
CT OR = 1.23; 1.13–1.33 0.36
CC OR = 1.0 0.28
11q23.1 rs3802842 [21] C11orf93 [48] CC OR = 1.35; 1.22–1.49 0
AC OR = 1.18; 1.11–1.25 0.21
AA OR = 1.0 0.79
Notes: Possible range of lifetime risk estimates: OR = 1.0 (6%) up to OR = 3.8 (23%). Ris
Cauc. = Caucasian.how to best combine risk estimates from different SNPs. At the end
of the pre-test education session, participants were given the option
of SNP testing for three research SNPs related to CRC risk (Table 1).
Interested participants provided a DNA sample using a mouthwash
oral rinse solution by standard collection procedures. CLIA-approved
genotyping was performed in the Genomics and Epigenomics Shared
Resource at the Lombardi Comprehensive Cancer Center at Georgetown
University. We disclosed results to participants 8 to 10 weeks later via
an in-person or telephone session with the genetic counselor using
individually-tailored, printed booklets. Participants who completed the
education sessions by telephone received the pre- and post-test printed
booklets bymail prior to the scheduled sessions. The post-test materials
provided individual lifetime risk estimates based on SNP results and
reviewed participants' other risk factors for CRC (e.g., family history, life-
style risk factors; see Fig. 1).
2.2.3. SNP panel and genotyping
We selected three SNPs for inclusion in the research panel based
on a reviewof the literature at the time of study initiation and our a priori
selection criteria: rs6983267 (8q24.21) [19], rs4779584 (CRAC1) [20],
and rs3802842 (11q23.1) [21] (Table 1). Selection criteria included: 1)
number of published studies examining the association (≥3 studies),
2) sample size of the studies (≥5000 cases and 5000 controls), 3) sample
demographics that were similar to the demographics of our study popu-
lation, and 4) statistical strength of the results. The three SNPs that met
our criteria were part of the commercially available DTC CRC panels at
the time of study initiation [22–24].
We processed and stored mouthwash samples as pellets at −80 °C
until analysis. We used allelic discrimination techniques based on real
time PCRmethodswith Taqman®probes for SNP analysis.Weperformed
PCR reactions on the ABI 7900HT sequence detection system (Applied
Biosystems, Foster City, CA). To ensure consistency,we randomly selected
20% of selected samples for repeat analysis.
2.3. Study assessments
In the baseline assessment conducted prior to the ﬁrst genomic
education session and testing, we assessed demographics, family and
personal history of cancer, prior CRC screening and polyp and bowel
disease history. We also assessed psychosocial and health behavior
variables at baseline, post-education, immediately post-test and at the
3-month follow-up. We assessed communication of SNP result variables
at the 3-month follow-up.
2.3.1. Psychosocial variables
Psychosocial variables included perceived risk for CRC (3-items:
absolute risk, comparative risk [25], numeric risk [26] and cancer
worry [27]). At the 3-month follow-up, we measured psychological re-
sponses to SNP testingusing an adapted version of theMultidimensionalrequencies [36] % of individuals with each genotype
by CRC family history
AA GUH Cauc. dbSNP AA dbSNP Cauc. CRC family history No CRC family
history
0.44 0.79 0.20 0.15 0.03
0.52 0.21 0.50 0.31 0.31
0.04 0 0.30 0.54 0.66
0 0.17 0.07 0 0.19
0.30 0.58 0.19 0.46 0.28
0.70 0.25 0.74 0.54 0.53
0.11 0.13 0.17 0.69 0.47
0.33 0.57 0.31 0.23 0.47
0.55 0.30 0.52 0.08 0.06
k estimates calculated using multiplicative model [23,32,33]. AA = African American;
Fig. 1. Genomic education materials: lifestyle and SNP risk information.
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126 K.D. Graves et al. / Genomics 102 (2013) 123–130Instrument of Cancer Risk Assessment [28]. Behavioral variables at base-
line, post-test and 3-months included face-valid items adapted from
behavioral screeners to assess self-reported behaviors related to CRC
risk: alcohol consumption, diet, physical activity [29,30] and smoking.
We also assessed whether participants had seen their primary care
physician, scheduled or completed appointments for CRC screening, and
intentions for screening [31]. At 3-months, we assessed communication
variables of participants' communication of SNP results to family mem-
bers or physicians.
3. Calculation
3.1. SNP risk estimation
We generated lifetime risk estimates using a multiplicative model
[23,32,33], ﬁrst multiplying the odds ratios (OR) of each genotype
and then multiplying the product by 6%, the average CRC population
risk [18–21]. With no consensus standard for combining SNP risk esti-
mates [34], we used the multiplicative model due to 1) the strong cor-
relation between results from alternative and multiplicative models
[33], 2) GWAS evidence that increasing numbers of risk alleles are asso-
ciated with greater risk [35], 3) use of the multiplicative model for esti-
mating increased risk of common genetic variants in other cancers [32]
and 4) use of this model by DTC testing companies [23].
3.2. Statistical analyses
Wecomputed descriptive statistics to characterize the demographics
of the sample and generated means, standard deviations and frequen-
cies of study variables. We used Pearson and Spearman correlations,
t-tests and χ2-tests to examine relationships between the SNP riskTable 2
Participant characteristics and bivariate predictors of selected psychosocial, communication
Variable CRC worry
M (SD)
Genetic testing
distress M (SD)
Intended to ha
screening % ye
Age (M = 58.3, SD = 10.4 years) t = 2.67⁎ t = −0.23 χ2 = 3.20±
b50 years (n = 9, 20%) 0.11 (0.33) 5.11 (3.10) 44.4%
≥50 years (n = 38, 80%) 0.57 (0.78) 5.43 (3.77) 13.8%
Sex t = −0.60 t = −0.62 χ2 = 0.63
Female (n = 26, 56%) 0.42 (0.65) 5.04 (3.72) 63.6%
Male (n = 21, 44%) 0.55 (0.83) 5.75 (3.80) 75.0%
Race t = 0.17 t = −0.04 χ2 = 0.03
Caucasian (n = 27, 57%) 0.46 (0.65) 5.39 (3.71) 68.0%
Non-Caucasian (n = 20, 43%) 0.50 (0.86) 5.33 (3.87) 70.6%
Education t = −0.19 t = 1.63 χ2 = 0.02
bCollege (n = 8, 17%) 0.43 (0.79) 7.43 (3.91) 71.4%
≥College (n = 39, 83%) 0.49 (0.73) 4.97 (3.62) 68.6%
Annual income (n = 42)a t = −0.57 t = 1.87± χ2 = 1.59
b$50,000 (n = 9, 21%) 0.38 (0.74) 7.63 (5.01) 50.0%
≥$50,000 (n = 33, 79%) 0.55 (0.77) 4.83 (3.40) 73.3%
Personal history: cancer t = −1.40 t = −0.54 χ2 = 0.16
No (n = 37; 79%) 0.40 (0.74) 5.23 (4.10) 67.7%
Yes (n = 10; 21%) 0.78 (0.67) 5.78 (1.97) 75.0%
Personal history: polyp t = 0.47 t = 0.43 χ2 = 4.11⁎
No (n = 29, 62%) 0.52 (0.70) 5.52 (3.96) 57.7%
Yes (n = 18, 38%) 0.41 (0.80) 5.12 (3.43) 87.5%
Family history: CRC t = −2.60⁎ t = −2.03⁎ χ2 = 1.14
No (n = 34, 72%) 0.31 (0.59) 4.69 (3.51) 64.5%
Yes (n = 13, 28%) 0.92 (0.90) 7.17 (3.83) 81.8%
BMI (M = 27.7,SD = 5.3) t = −2.78⁎⁎ t = 1.68 χ2 = 0.50
b25 (n = 16, 34%) 0.14 (0.36) 6.71 (4.41) 61.5%
≥25 (n = 31, 66%) 0.63 (0.81) 4.73 (3.26) 72.4%
SNP score (n = 45 tested) t = −0.87 t = 1.24 χ2 = 1.70
Low (>12; n = 36; 80%) 0.43 (0.70) 5.71 (3.97) 73.5%
High (≤12; n = 9; 20%) 0.67 (0.87) 4.00 (2.23) 50.0%
Note: CRC = colorectal cancer. Results for 3-month outcomes presented as means and stan
a 5 participants chose not to answer this question.
± p b .10.
⁎ p b .05.
⁎⁎ p b .01.scores and psychosocial, behavioral and communication variables in bi-
variate analyses. We used simultaneous multiple linear regression
models to evaluate the independent impact of SNP test results, demo-
graphic and clinical characteristics on the psychosocial, behavioral and
communication outcomes.
4. Results
Of 157 primary care patients we approached, 47 (30%) chose to par-
ticipate. Primary reasons for non-participation were lack of interest or
time. Study decliners did not differ from participants on age, gender or
race. Participants had a mean age of 58.3 years (SD = 10.4 years;
range 40–84 years) and 21% had a personal history of cancer (n = 10;
cancers included breast, prostate, skin, sarcoma, thyroid, endometrial,
bladder and leukemia). Slightly more than one-quarter (27%) had a
family history of CRC (see Table 2). All participants reported having
some form of health insurance. Table 2 includes information about par-
ticipant characteristics.
Forty-ﬁve of the 47 participants (96%) opted for SNP testing after a
genomic education session with a certiﬁed genetic counselor. Partici-
pants averaged 2.5 of 6 possible SNP risk alleles with an estimated
10% lifetime risk (SD = 2.3%, sample range = 6.0% to 15.0%; possible
range = 6% to 23%). Twenty percent of the sample had a risk at or
above 12% (twice average risk). Table 1 presents the allele frequencies
for each of the three SNPs in both our sample and population estimates
from dbSNP [36].
4.1. Psychosocial outcomes
Immediately post-test, SNP risk scores were unrelated to perceived
CRC risk or CRC worry. At the 3-month post-test, bivariate analysesand behavioral outcomes at 3-months.
ve CRC
s
Positive dietary
changes % yes
Positive exercise
changes % yes
Shared results:
family % yes
Shared results:
physician % yes
χ2 = 0.02 χ2 = 0.02 χ2 = 0.20 χ2 = 1.95
44.4% 37.5% 55.6% 20.0%
47.1% 40.0% 47.4% 54.6%
χ2 = 0.64 χ2 = 0.32 χ2 = 0.56 χ2 = 0.90
52.2% 43.5% 53.9% 40.0%
40.0% 35.0% 42.9% 58.3%
χ2 = 1.71 χ2 = 1.21 χ2 = 2.24 χ2 = 4.49⁎
38.5% 46.2% 59.3% 31.3%
58.8% 29.4% 36.8% 72.7%
χ2 = 0.38 χ2 = 0.04 χ2 = 5.12⁎ χ2 = 3.63±
57.1% 42.9% 12.5% 100%
44.4% 38.9% 56.4% 41.7%
χ2 = 0.53 χ2 = 1.10 χ2 = 0.94 χ2 = 4.80⁎
57.1% 25.0% 33.3% 100%
41.9% 45.2% 51.5% 40.0%
χ2 = 0.37 χ2 = 1.22 χ2 = 0.01 χ2 = 0.34
44.1% 35.3% 48.7% 45.5%
55.6% 55.6% 50.0% 60.0%
χ2 = 4.74⁎ χ2 = 5.63⁎ χ2 = 0.51 χ2 = 0.02
59.3% 53.9% 44.8% 47.1%
25.0% 17.7% 55.6% 50.0%
χ2 = 1.16 χ2 = 0.03 χ2 = 0.17 χ2 = 0.11
51.6% 38.7% 47.1% 50.0%
33.3% 41.7% 53.9% 42.9%
χ2 = 0.97 χ2 = 0.60 χ2 = 1.27 χ2 = 0.11
35.7% 30.8% 37.5% 42.9%
51.7% 43.3% 54.8% 50.0%
χ2 = 4.48⁎ χ2 = 0.89 χ2 = 0.20 χ2 = 0.01
38.2% 42.9% 47.4% 47.6%
77.8% 25.0% 55.6% 50.0%
dard deviations. BMI = Body Mass Index.
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risk scores (r = .22, p = .06), family history of CRC [Satterthwaite
t (df =13.5) = −2.68, p = .02], personal history of cancer [t (40) =
−2.60, p = .01] and baseline numeric perceived risk (r = .76,
p b .0001). Perceived risk scores by personal cancer history and SNP
risk score categories are shown in Table 3. Age, gender and race were
not related to perceived CRC risk at the 3-month post-test. Bivariate as-
sociations between SNP risk score categories (high, meaning twice av-
erage risk, vs. low) and study outcomes are presented in Table 2. In
multivariate analyses, higher SNP risk scores no longer remained an in-
dependent signiﬁcant predictor of higher numeric perceived CRC risk at
3-months (β = .15, p = .08). Baseline pre-education numeric per-
ceived CRC risk and both personal history of cancer and family history
of CRC contributed signiﬁcantly to the ﬁnal model of perceived numeric
risk 3-month post-results, F (4,36) = 23.8, p b .001, R2 = .70. SNP risk
scores were not related to absolute or comparative perceived risk, CRC
worry or genetic-testing distress at the post-test or 3-month assess-
ments. Overall, using our adapted measure, participants reported very
low levels of distress related to genomic testing (M = 5.4, SD = 3.8;
possible score range 0–16) [28].
4.2. Behavioral outcomes
Most participants (89%) were currently adherent to CRC screening
guidelines. Of the remaining 11% of participants (n = 5) who were
non-adherent at baseline, four reported intentions to screen immedi-
ately post-test. None of these individuals had obtained screening by
the 3-month follow-up, although three participants maintained in-
tentions to screen within the next couple of years.
Immediately post-test, about half of the sample reported plans to
improve physical activity (64%) and nutrition (48%). At the 3-month
follow-up, 56% and 55% reported actual changes to exercise and eatingTable 3
Perceived numeric risk of colorectal cancer before and after genomic risk education and
testing.
Baseline Post-education Post-test 3-month
follow-up
M (SD) possible range = 0–100
Overall sample (n = 45) 32.45 (25.0) 23.24 (21.9) 23.7 (24.7) 24.1 (25.1)
Personal cancer history
Yes (n = 8)a 43.1 (25.2) 39.9 (23.0) 43.3 (21.9) 43.0 (32.2)
Ca Hx and high SNP
score (n = 2)
50.0 (0) 50.0 (0) 35.0 (21.2) 50.0 (14.1)
Ca Hx and low SNP
score (n = 6)
40.8 (29.4) 36.5 (26.2) 46.6 (23.6) 40.7 (37.2)
No (n = 35) 27.8 (24.2) 18.3 (18.4) 19.8 (22.9) 19.1 (21.0)
No Ca Hx and high
SNP score (n = 7)
28.0 (23.9) 23.0 (25.3) 27.1 (24.0) 25.2 (21.5)
No Ca Hx and low
SNP score (n = 28)
27.8 (24.8) 16.7 (16.2) 17.7 (22.6) 17.8 (21.1)
Family history of CRC
Yes (n = 13)
Family Hx and high
SNP score (n = 1)
10.0 8.0 20.0 40.0
Family Hx and low
SNP score (n = 12)
41.3 (27.9) 32.8 (26.1) 38.3 (28.9) 42.6 (33.8)
No (n = 31)b
No family Hx
and high SNP score
(n = 8)
38.3 (21.4) 32.8 (25.0) 30.0 (23.7) 30.1 (23.6)
No family Hx and low
SNP score (n = 23)
23.4 (22.5) 17.9 (17.6) 15.8 (20.1) 11.9 (11.8)
Note: Possible score range on perceived numeric risk is 0 (deﬁnitely won't get CRC)
to100 (deﬁnitely will get CRC). Ca Hx = cancer history. High SNP score ≥ 12% lifetime
CRC risk estimate. Low SNP score ≥ 12% lifetime CRC risk estimate.
a Missing data for one participant with a personal history of cancer and another par-
ticipant with cancer opted not to pursue genomic testing.
b Missing numeric perceived risk data from one person without a family history of
disease.behaviors, respectively, since the second genomic education session and
receipt of SNP results. Reported changes in eating behavior included
reduced red meat and increased vegetable and ﬁsh consumption.
Reported changes in exercise behavior included increased walking or in-
creased frequency of physical activity. In bivariate analyses, SNP risk score
was related to participants' reported engagement inmoderate exercise at
3-months (r = .48, p b .001). Inmultivariate logistic regression analyses,
SNP risk scorewas not an independent predictor of changes in exercise at
3-months (OR = 1.43; 95% CI = 0.97–2.10) in a regression model that
also included baseline levels of exercise behavior, personal history of
having a polyp, personal history of cancer, family history of CRC, and
body mass index. Only not having a personal history of a colon polyp
was statistically signiﬁcantly associatedwith reported changes in exercise
at 3-months (OR = 10.4; 95% CI = 1.5–74.1). SNP risk scores were not
related to reported changes in eating behavior.
Only 2 participants reported smoking at baseline; immediately
post-test, both participants reported intentions of quitting smoking
within the next 6 months.We did not assess intentions to quit smoking
at the 3-month follow-up. No consistent changeswere noted for alcohol
consumption.
4.3. Communication outcomes
By the 3-month follow-up, more than half of participants (64%)
reported talking about their SNP results with other people. Among
participants who shared their SNP results, 68% talked with a spouse/
signiﬁcant other, 42%with children, 32%with a sister, 20%with a brother,
and 13% with parents. Among participants who reported at the 3-month
follow-up that they had an appointment with their primary care physi-
cian since receipt of the SNP test results (n = 26), 50% shared results
with their physician, representing 28% of all study participants. More
African American participants reported sharing SNP results with their
physicians than Caucasian participants, χ2 = 4.5, p = .009. Sharing of
SNP results was not related to SNP risk score, cancer worry or CRC per-
ceived risk. In bivariate analyses, only family history of CRC was related
to sharing of results with brothers (r = .56, p = .007), although this re-
lationship was not evident for the sharing of results to any other family
members or physicians and was not signiﬁcant in multivariate analyses.
5. Discussion
For genomic discoveries to improve public health, clinical and trans-
lational researchmust begin to apply genomic risk information in ways
that evaluate a range of outcomes [15]. A major goal of translational
research is to establish whether genomic risk information has utility
in the area of disease prevention [16]. We conducted an innovative
pilot study to prospectively evaluate psychosocial, behavioral and com-
munication outcomes following genomic risk education and testing of a
research panel of three SNPs related to CRC risk. Study participants had
a high rate of SNP-test uptake, reported increases in physical activity
and healthy eating following risk education, and had moderate rates
of disclosure of results to family and physicians. We found no evidence
that the receipt of genomic risk information increased cancer worry or
distress related to testing. To our knowledge, this is the ﬁrst study to re-
port a range of outcomes following genomic education and testing for
CRC risk among a diverse sample of primary care patients.
The small but growing literature on outcomes following genomic
testing for risk related to common, complex diseases such as cancer sug-
gests that people are interested in obtaining this type of information,
even when the risks, beneﬁts and uncertainty of the information are
carefully explained [13,18]. Approximately one-third of the individuals
approached to participate in the study agreed and among study partic-
ipants, almost all of themopted for genomic testing. The high rate of test
uptake among study participants is consistent with recent research re-
lated to interest in genomic testing [37,38]. These high rates are likely
because individuals who agree to participate in genetics and genomics
128 K.D. Graves et al. / Genomics 102 (2013) 123–130research may be interested in learning more about genomic risk. We
were unable to examine predictors of test uptake as only two partici-
pants declined testing.
We found that participants in our study had an average lifetime
CRC risk of 10%. Moreover, over one-quarter of our sample had a family
history of CRC and one-ﬁfth of participants were themselves cancer sur-
vivors (although no participants had a history of CRC). These factors in-
dicate that our sample includes individuals at increased risk of CRC.
Personal and family history of diseasemay lead to greater salience of ge-
nomic risk information [7]. Our study ﬁndings that SNP risk estimates
were unrelated to reports of behavior change provide information
about how people interpret and use different types of risk information.
In the current study, the mechanism of change for improvements in
self-reported health behaviors is likely the risk education provided by
certiﬁed genetic counselors rather than the SNP results themselves.
For example, genetic counselors emphasized how individual risk factors,
such as high body mass index, can impact future risk.
Results from this pilot study suggest that participants who agree
to a study about genomic risk for CRC do not experience increased
distress or cancerworry. These ﬁndings are consistentwith other studies
indicating that genomic testing for susceptibility alleles does not lead to
signiﬁcant emotional concerns [6]. Likewise, these ﬁndings are not
surprising given that the receipt of genetic test results for much higher
penetrance genes such as BRCA1/BRCA2 does not appear to cause sub-
stantially increased distress over time [39].
Our ﬁndings that SNP risk scores were not independently associated
with numeric perceived risk contrast with earlier literature on genomic
feedback and smoking behavior which indicates that genomic informa-
tion impacts perceived risk of lung cancer [1]. Recent results from
vignette-based research indicate that higher hypothetical SNP-based
risk translated into higher perceptions of disease risk [40]. No changes
in perceived risk related to SNP risk scores may be a reﬂection of the ge-
netic counselors' emphasis on the lack of clinical utility of SNP risk infor-
mation.We used several visual, text-based and graphical representations
of genomic risk [41]. An important area of future study will be to investi-
gate ways to combine other risk factors (e.g., lifestyle, family or personal
history) and genomic risk information into a singlemetric to appropriate-
ly communicate more complete risk information. Relevant to perceived
risk, we elected to include only SNPs that increased risk as part of our
research SNP-panel and thus no participants received risk scores below
average risk.
Limited evidence to date supports behavior change following ge-
nomic risk testing. Our approach combining education about lifestyle,
family history and genomic risk factors yielded modest self-reported
behavior change at the 3-month post-test. Reduced red meat con-
sumption, increased ﬁsh and vegetable intake and increased walking
and other exercise are behavior changes that relate to CRC risk reduc-
tion [42]. Behavior change was evident despite the lack of clinical util-
ity of the SNP results and the lack of impact of SNP risk itself on
behavior change. These ﬁndings suggest that 1) risk education ses-
sions with certiﬁed genetic counselors that discussed personal, family
history and lifestyle risk feedback increased the salience of improving
certain behaviors for CRC risk reduction and/or 2) more deﬁnitive ge-
nomic risk information, including higher levels of increased risk or
less uncertainty surrounding the meaning of SNP-risk information,
might be needed for a stronger catalyst of behavior change. As the ge-
nomic risk information was presented together with individual and
family history risk feedback, the present results do not resolve wheth-
er genomic risk information alone has personal utility for people.
These data suggest that it may be crucial to identify intervention ap-
proaches for leveraging the apparent motivational increase of risk
feedback and to test the impact of such feedback when it is given
with and without genomic risk information. A test of risk feedback
with and without genomic risk information would provide evidence
of whether genomic risk information has clinical utility in terms of
sustained behavior change [38]. Future research also will need toconﬁrm if participants' self-reported health behavior change reﬂects ac-
tual sustained changes using objective behavioral and health outcomes
measures (e.g., weight loss, improved ﬁtness). Our initial report pro-
vides preliminary evidence suggesting that CRC risk education may
lead to intentions and actual efforts to modify behavior, separate from
the level of genomic risk. This is consistent with research on risk feed-
back related to tobacco, in which there is evidence for increased quit at-
tempts but more limited evidence for long-term behavior change.
Beyond the reported changes in physical activity and dietary behavior,
our results contribute to the literature as among the ﬁrst studies to report
on communication of results following genomic testing for a common
complex disease. Prior research in this area has explored whether early
adopters of DTC genomic testing shared resultswith healthcare providers
[7]. Our ﬁnding that the sharing of SNP resultswasmore common among
African American participants compared to Caucasian participants is
interesting. Perhaps this increased sharing of results is due to greater
salience of CRC given the higher rate of CRC incidence and mortality in
African Americans [43]. Future work can explore the possible reasons
for this differential rate of disclosure by race. Our ﬁnding that almost
two-thirds of the sample discussed their SNP results with family or a
health care provider suggests additional avenues for research. First, future
studies can explore the speciﬁc topics related to genomic risk information
that people share, including whether the information impacts the per-
ceived risk of family members. Second, investigators can examine how
genomic risk information is received by physicians and whether this
information inﬂuences clinical care [44]. Participants appeared to discuss
their SNP results regardless of their SNP risk score, suggesting that level of
genomic risk may not be related to result communication.
A number of caveats should be considered when interpreting
study ﬁndings. First, this was a pilot study with a small sample size
of which 20% had been previously affected with cancer. Our sample
may have been more open to the receipt of information about cancer
risks and may also have been more familiar with the concepts of
genetic or genomic risk for cancer. These biases could limit the gener-
alizability of results to other samples. Likewise, with 45 individuals
who tested, we were underpowered to detect small to moderate rela-
tionships (e.g., effect sizes below 0.36) between SNP risk scores and
our study outcomes. Despite the small size, our sample was diverse
in terms of participants' self-reported race. Although we captured
general reasons for non-participation among study decliners, we did
not speciﬁcally ask if patients declined because theywere not interested
in genomic testing. Our recruitment from a primary care clinic extends
prior work that has largely focused on early-adopters of DTC genomic
testing or individuals from a managed care organization [10,45]. Clinic-
based recruitment also likely inﬂuenced the high baseline rate of adher-
ence to CRC screening guidelines (89%) in our sample, a ﬁnding which
could reﬂect a high level of engagement with health care and interest in
health-related information such as genomic risk for CRC. Second, we
offered free testing and education sessions with a certiﬁed genetic
counselor within the context of the study, likely inﬂuencing the rate of
test uptake. Our inclusion of a genetics professional for pre- and post-
test education makes the present ﬁndings different from most DTC
genomic-testing models [44] and may have contributed to the lower
rates of worry and perhaps greater understanding of the limited utility
of SNP-based genomic information. Third, behavior change and commu-
nication of results were assessed through participant self-report and thus
subject to the potential biases associated with self-reports of certain
health behavior [46,47]. Future research can includemore objectivemea-
sures of these outcomes. Finally, we did not adjust the lifetime CRC risks
by participants' age when providing the SNP risk information. For exam-
ple, an individual who is 65 years old with an identical SNP proﬁle to a
45 year old would have a lower lifetime risk of CRC. In our study, the ge-
netic counselors discussed this issue, but we did not provide an age-
adjusted quantitative risk estimate. Adjusting genomic risk estimates by
age or providing risk estimates for a deﬁned interval is straightforward
and should be included in future work.
129K.D. Graves et al. / Genomics 102 (2013) 123–1306. Conclusions
Our study is among the ﬁrst to explore the impact of genomic risk
information on a range of outcomes in a sample of primary care patients.
Exploring ways to appropriately translate genomic discoveries into clini-
cal applications and preventive health interventions will accelerate our
ability to improve the clinical and personal utility of this information.
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